Search

Displaying results 1031 - 1040 of 10000 in total
  1. Drug

    Coagulation Factor IX (Recombinant)

    go.drugbank.com/drugs/DB00100
    Approved

    It is not derived from human blood (unlike human Factor IX complex), and is instead produced by a genetically engineered Chinese hamster ovary (CHO) cell line that secretes recombinant Factor IX into cell … Recombinant Factor IX is indicated for the control and prevention of bleeding episodes in adult and pediatric patients with congenital factor IX deficiency (Hemophilia B).

  2. Indication

    Metastatic Bone Sarcomas

    go.drugbank.com/conditions/DBCOND0038791
    Drugs: Doxorubicin
    Synonyms: Metastatic Bone sarcoma, Metastatic Bone Sarcomas
  3. Drug

    Carglumic acid

    go.drugbank.com/drugs/DB06775
    ApprovedInvestigational

    Food and Drug Administration (FDA) on 18 March 2010. … Carglumic acid is a drug used for the treatment of hyperammonemia in patients with a deficiency in N-acetyl glutamate synthase.

    Synonyms: N-Carbamylglutamate, N-Carbamyl-L-glutamate
  4. Drug

    Etidronic acid

    go.drugbank.com/drugs/DB01077
    ApprovedInvestigational

    [A203111] Etidronic acid was granted FDA approval on 1 September 1977.[L13901] … [A1923] Etidronate’s use has decreased over the years in favor of the third generation, nitrogen containing bisphosphonate [zoledronic acid], [ibandronic acid], [minodronic acid], and [risedronic acid]

    Categories: Bone Density Conservation Agents, Drugs for Treatment of Bone Diseases
  5. Drug

    Darolutamide

    go.drugbank.com/drugs/DB12941
    ApprovedInvestigational

    [A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019.[L10887] … This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists.

    Categories: Antiandrogens, non-steroidal
  6. Drug

    Tropicamide

    go.drugbank.com/drugs/DB00809
    Approved

    [A230103] Usually available in ophthalmic formulations, tropicamide is used to cause mydriasis and cycloplegia for eye exams or ocular procedures. … Tropicamide is an alkaloid atropine‐derived anticholinergic drug and a non‐selective antagonist of muscarinic acetylcholine (mACh) receptors.

  7. Drug

    Depemokimab

    go.drugbank.com/drugs/DB18846
    ApprovedInvestigational

    [A275338] Approved by the FDA on December 16, 2025, depemokimab is indicated as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in adult and paediatric patients … [A275338, L54758] Its long duration of action is granted by seven amino acid substitutions in the heavy chain sequence.

  8. Drug

    Ranibizumab

    go.drugbank.com/drugs/DB01270
    ApprovedInvestigational

    BYOOVIZ, a biosimilar of LUCENTIS, was approved by Health Canada in March 2022, making it the first and only biosimilar drug of ranibizumab available in Canada. … In order to improve drug delivery to the target organ, ranibizumab is available for intravitreal use.

    Products: LUCENTIS 10 MG/ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE, LUCENTIS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 1.65mg/0.165ml
  9. Drug

    Lumacaftor

    go.drugbank.com/drugs/DB09280
    ApprovedInvestigational

    Consequently, lumacaftor increases successful production of CFTR ion channels and the total number of receptors available for use at the cell membrane for fluid and ion transport. … results in impaired production of the CFTR protein, thereby causing a significant reduction in the amount of ion transporter present on cell membranes.

  10. Target

    Bone morphogenetic protein 4

    go.drugbank.com/bio_entities/BE0009000
    TargetHumans

    Growth factor of the TGF-beta superfamily that plays essential roles in many developmental processes, including neurogenesis, vascular development, angiogenesis and osteogenesis (PubMed:31363885). Acts in concert with PTHLH/PTHRP to stim...

    Polypeptides: Bone morphogenetic protein 4Synonyms: Bone morphogenetic protein 2B